The National Cancer Institute awarded The Broad Institute, Inc. a $143,788 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to support research on pediatric low-grade gliomas. The grant aims to study how the KIAA1549-BRAF fusion gene, a common driver mutation in these brain tumors, is activated and regulated. Specifically, the research will investigate the role of the POMT enzyme complex and protein O-mannosylation in KIAA1549-BRAF signaling and tumor cell survival. The project will also explore whether proteolytic cleavage of the KIAA1549-BRAF fusion is necessary for BRAF activation. This work is expected to provide new insights into the molecular mechanisms underlying these pediatric brain cancers and inform the development of more effective targeted therapies. The grant period runs from February 1, 2025 to January 31, 2027.
Generated 3/4/25, 4:42 AM